Tingyi Xia

Summary

Affiliation: Sun Yat-sen University
Country: China

Publications

  1. ncbi Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer
    Tingyi Xia
    Department of Radiation Oncology, Air Force General Hospital, Beijing, People s Republic of China
    Int J Radiat Oncol Biol Phys 66:117-25. 2006
  2. pmc SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2
    Hongqi Li
    Department of Radiation Oncology, Air Force General Hospital, Beijing 100142, P R China
    Int J Oncol 43:1420-30. 2013
  3. doi [A randomized phase I/II trial to compare weekly usage with triple weekly usage of paclitaxel in concurrent radiochemotherapy for patients with locally advanced non-small cell lung cancer]
    Anhui Shi
    Department of Radiation Oncology, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Beijing, China
    Zhongguo Fei Ai Za Zhi 14:227-32. 2011

Collaborators

Detail Information

Publications3

  1. ncbi Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer
    Tingyi Xia
    Department of Radiation Oncology, Air Force General Hospital, Beijing, People s Republic of China
    Int J Radiat Oncol Biol Phys 66:117-25. 2006
    ..To evaluate the efficacy and toxicity of hypofractionated stereotactic body radiotherapy in patients with Stage I/II non-small-cell lung cancer...
  2. pmc SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2
    Hongqi Li
    Department of Radiation Oncology, Air Force General Hospital, Beijing 100142, P R China
    Int J Oncol 43:1420-30. 2013
    ....
  3. doi [A randomized phase I/II trial to compare weekly usage with triple weekly usage of paclitaxel in concurrent radiochemotherapy for patients with locally advanced non-small cell lung cancer]
    Anhui Shi
    Department of Radiation Oncology, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Beijing, China
    Zhongguo Fei Ai Za Zhi 14:227-32. 2011
    ..The aim of this study is to compare weekly usage with triple weekly usage of paclitaxel in concurrent radiochemotherapy for patients with LANSCLC, and to obtain the best paclitaxel regimen in the concurrent radiochemotherapy...